Report cover image

Global Kidney Cancer Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 195 Pages
SKU # APRC20359447

Description

Summary

According to APO Research, the global Kidney Cancer market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Kidney Cancer is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Kidney Cancer is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Kidney Cancer market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Kidney Cancer is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Kidney Cancer market include Aveo Pharmaceuticals, Bristol-Myers Squibb, Exelixis, Hikma Pharmaceuticals, Sun Pharmaceutical, Amgen, Bayer, Pfizer and Roche, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Kidney Cancer, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Kidney Cancer, also provides the value of main regions and countries. Of the upcoming market potential for Kidney Cancer, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Kidney Cancer revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Kidney Cancer market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Kidney Cancer company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Kidney Cancer Segment by Company

Aveo Pharmaceuticals
Bristol-Myers Squibb
Exelixis
Hikma Pharmaceuticals
Sun Pharmaceutical
Amgen
Bayer
Pfizer
Roche
Merck
Novartis
Eisai
Kidney Cancer Segment by Type

Targeted Therapy
Immunotherapy
Surgery
Other
Kidney Cancer Segment by Application

Renal Cell Carcinoma
Renal Pelvis Cancer
Other
Kidney Cancer Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Kidney Cancer status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Kidney Cancer key companies, revenue, market share, and recent developments.
3. To split the Kidney Cancer breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Kidney Cancer market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Kidney Cancer significant trends, drivers, influence factors in global and regions.
6. To analyze Kidney Cancer competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Kidney Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney Cancer.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Kidney Cancer industry.
Chapter 3: Detailed analysis of Kidney Cancer company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Kidney Cancer in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Kidney Cancer in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Table of Contents

195 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Kidney Cancer Market Size, 2020 VS 2024 VS 2031
1.3 Global Kidney Cancer Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Kidney Cancer Market Dynamics
2.1 Kidney Cancer Industry Trends
2.2 Kidney Cancer Industry Drivers
2.3 Kidney Cancer Industry Opportunities and Challenges
2.4 Kidney Cancer Industry Restraints
3 Kidney Cancer Market by Company
3.1 Global Kidney Cancer Company Revenue Ranking in 2024
3.2 Global Kidney Cancer Revenue by Company (2020-2025)
3.3 Global Kidney Cancer Company Ranking (2023-2025)
3.4 Global Kidney Cancer Company Manufacturing Base and Headquarters
3.5 Global Kidney Cancer Company Product Type and Application
3.6 Global Kidney Cancer Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Kidney Cancer Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Kidney Cancer Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Kidney Cancer Market by Type
4.1 Kidney Cancer Type Introduction
4.1.1 Targeted Therapy
4.1.2 Immunotherapy
4.1.3 Surgery
4.1.4 Other
4.2 Global Kidney Cancer Sales Value by Type
4.2.1 Global Kidney Cancer Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Kidney Cancer Sales Value by Type (2020-2031)
4.2.3 Global Kidney Cancer Sales Value Share by Type (2020-2031)
5 Kidney Cancer Market by Application
5.1 Kidney Cancer Application Introduction
5.1.1 Renal Cell Carcinoma
5.1.2 Renal Pelvis Cancer
5.1.3 Other
5.2 Global Kidney Cancer Sales Value by Application
5.2.1 Global Kidney Cancer Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Kidney Cancer Sales Value by Application (2020-2031)
5.2.3 Global Kidney Cancer Sales Value Share by Application (2020-2031)
6 Kidney Cancer Regional Value Analysis
6.1 Global Kidney Cancer Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Kidney Cancer Sales Value by Region (2020-2031)
6.2.1 Global Kidney Cancer Sales Value by Region: 2020-2025
6.2.2 Global Kidney Cancer Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Kidney Cancer Sales Value (2020-2031)
6.3.2 North America Kidney Cancer Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Kidney Cancer Sales Value (2020-2031)
6.4.2 Europe Kidney Cancer Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Kidney Cancer Sales Value (2020-2031)
6.5.2 Asia-Pacific Kidney Cancer Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Kidney Cancer Sales Value (2020-2031)
6.6.2 South America Kidney Cancer Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Kidney Cancer Sales Value (2020-2031)
6.7.2 Middle East & Africa Kidney Cancer Sales Value Share by Country, 2024 VS 2031
7 Kidney Cancer Country-level Value Analysis
7.1 Global Kidney Cancer Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Kidney Cancer Sales Value by Country (2020-2031)
7.2.1 Global Kidney Cancer Sales Value by Country (2020-2025)
7.2.2 Global Kidney Cancer Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Kidney Cancer Sales Value Growth Rate (2020-2031)
7.3.2 USA Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Kidney Cancer Sales Value Growth Rate (2020-2031)
7.4.2 Canada Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Kidney Cancer Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Kidney Cancer Sales Value Growth Rate (2020-2031)
7.6.2 Germany Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Kidney Cancer Sales Value Growth Rate (2020-2031)
7.7.2 France Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.7.3 France Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Kidney Cancer Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Kidney Cancer Sales Value Growth Rate (2020-2031)
7.9.2 Italy Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Kidney Cancer Sales Value Growth Rate (2020-2031)
7.10.2 Spain Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Kidney Cancer Sales Value Growth Rate (2020-2031)
7.11.2 Russia Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Kidney Cancer Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Kidney Cancer Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Kidney Cancer Sales Value Growth Rate (2020-2031)
7.14.2 China Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.14.3 China Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Kidney Cancer Sales Value Growth Rate (2020-2031)
7.15.2 Japan Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Kidney Cancer Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Kidney Cancer Sales Value Growth Rate (2020-2031)
7.17.2 India Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.17.3 India Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Kidney Cancer Sales Value Growth Rate (2020-2031)
7.18.2 Australia Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Kidney Cancer Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Kidney Cancer Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Kidney Cancer Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Kidney Cancer Sales Value Growth Rate (2020-2031)
7.22.2 Chile Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Kidney Cancer Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Kidney Cancer Sales Value Growth Rate (2020-2031)
7.24.2 Peru Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Kidney Cancer Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Kidney Cancer Sales Value Growth Rate (2020-2031)
7.26.2 Israel Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Kidney Cancer Sales Value Growth Rate (2020-2031)
7.27.2 UAE Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Kidney Cancer Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Kidney Cancer Sales Value Growth Rate (2020-2031)
7.29.2 Iran Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Kidney Cancer Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Kidney Cancer Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Kidney Cancer Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Kidney Cancer Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Aveo Pharmaceuticals
8.1.1 Aveo Pharmaceuticals Comapny Information
8.1.2 Aveo Pharmaceuticals Business Overview
8.1.3 Aveo Pharmaceuticals Kidney Cancer Revenue and Gross Margin (2020-2025)
8.1.4 Aveo Pharmaceuticals Kidney Cancer Product Portfolio
8.1.5 Aveo Pharmaceuticals Recent Developments
8.2 Bristol-Myers Squibb
8.2.1 Bristol-Myers Squibb Comapny Information
8.2.2 Bristol-Myers Squibb Business Overview
8.2.3 Bristol-Myers Squibb Kidney Cancer Revenue and Gross Margin (2020-2025)
8.2.4 Bristol-Myers Squibb Kidney Cancer Product Portfolio
8.2.5 Bristol-Myers Squibb Recent Developments
8.3 Exelixis
8.3.1 Exelixis Comapny Information
8.3.2 Exelixis Business Overview
8.3.3 Exelixis Kidney Cancer Revenue and Gross Margin (2020-2025)
8.3.4 Exelixis Kidney Cancer Product Portfolio
8.3.5 Exelixis Recent Developments
8.4 Hikma Pharmaceuticals
8.4.1 Hikma Pharmaceuticals Comapny Information
8.4.2 Hikma Pharmaceuticals Business Overview
8.4.3 Hikma Pharmaceuticals Kidney Cancer Revenue and Gross Margin (2020-2025)
8.4.4 Hikma Pharmaceuticals Kidney Cancer Product Portfolio
8.4.5 Hikma Pharmaceuticals Recent Developments
8.5 Sun Pharmaceutical
8.5.1 Sun Pharmaceutical Comapny Information
8.5.2 Sun Pharmaceutical Business Overview
8.5.3 Sun Pharmaceutical Kidney Cancer Revenue and Gross Margin (2020-2025)
8.5.4 Sun Pharmaceutical Kidney Cancer Product Portfolio
8.5.5 Sun Pharmaceutical Recent Developments
8.6 Amgen
8.6.1 Amgen Comapny Information
8.6.2 Amgen Business Overview
8.6.3 Amgen Kidney Cancer Revenue and Gross Margin (2020-2025)
8.6.4 Amgen Kidney Cancer Product Portfolio
8.6.5 Amgen Recent Developments
8.7 Bayer
8.7.1 Bayer Comapny Information
8.7.2 Bayer Business Overview
8.7.3 Bayer Kidney Cancer Revenue and Gross Margin (2020-2025)
8.7.4 Bayer Kidney Cancer Product Portfolio
8.7.5 Bayer Recent Developments
8.8 Pfizer
8.8.1 Pfizer Comapny Information
8.8.2 Pfizer Business Overview
8.8.3 Pfizer Kidney Cancer Revenue and Gross Margin (2020-2025)
8.8.4 Pfizer Kidney Cancer Product Portfolio
8.8.5 Pfizer Recent Developments
8.9 Roche
8.9.1 Roche Comapny Information
8.9.2 Roche Business Overview
8.9.3 Roche Kidney Cancer Revenue and Gross Margin (2020-2025)
8.9.4 Roche Kidney Cancer Product Portfolio
8.9.5 Roche Recent Developments
8.10 Merck
8.10.1 Merck Comapny Information
8.10.2 Merck Business Overview
8.10.3 Merck Kidney Cancer Revenue and Gross Margin (2020-2025)
8.10.4 Merck Kidney Cancer Product Portfolio
8.10.5 Merck Recent Developments
8.11 Novartis
8.11.1 Novartis Comapny Information
8.11.2 Novartis Business Overview
8.11.3 Novartis Kidney Cancer Revenue and Gross Margin (2020-2025)
8.11.4 Novartis Kidney Cancer Product Portfolio
8.11.5 Novartis Recent Developments
8.12 Eisai
8.12.1 Eisai Comapny Information
8.12.2 Eisai Business Overview
8.12.3 Eisai Kidney Cancer Revenue and Gross Margin (2020-2025)
8.12.4 Eisai Kidney Cancer Product Portfolio
8.12.5 Eisai Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.